Real World Evidence (RWE) Solutions Market by Component [Datasets, EMR, Services], Application [Drug Development and Approvals (Oncology, Neurology, Immunology), Market Access, Medical Device Development], End User - Forecast to 2027

  • Report ID:MRHC - 104253
  • Pages: 194
  • Nov 2020
  • Formats*: PDF
  • Category: Healthcare
  • Delivery: 2 to 4 Hours

1.    Introduction
        1.1.    Market Definition
        1.2.    Market Ecosystem
        1.3.    Currency
        1.4.    Key Stakeholders

2.    Research Methodology
        2.1.    Research Process
        2.2.    Data Collection & Validation
                   2.2.1.    Secondary Research
                   2.2.2.    Primary Research
        2.3.    Market Assessment
                   2.3.1.    Market Size Estimation
                                2.3.1.1.    Bottom-Up Approach
                                2.3.1.2.    Top-Down Approach
                                2.3.1.3.    Growth Forecast
                   2.3.2.    Market Share Analysis
        2.4.    Assumptions for the Study
        2.5.    Limitations for the Study        
        
3.    Executive Summary                     

4.    Market Insights             
        4.1.     Introduction        
        4.2.     Drivers         
                    4.2.1.     Growing Burden of Chronic Diseases in Geriatric Population    
                    4.2.2.     Delays in Drug Development and the Subsequent Increase in Development Costs    
                    4.2.3.     Rising Focus Towards Personalized Healthcare    
                    4.2.4.     Shift Towards Value-Based Care    
                    4.2.5. Impact Assessment of COVID-19    
                    4.2.6.  Rapidly Growing Big Data in Healthcare             
        4.3.    Restraints    
                     4.3.1.    Reluctance to Rely on Real-World Studies            
         4.4.     Challenges        
                   4.4.1.     Lack of Standardized Methodologies to Develop RWE            
        4.5.     Opportunities        
                     4.5.1.     Emerging Economies     
                     4.5.2.    Rising Focus on End-to-End RWE Services    
                     4.5.3.    Rising Adoption of Wearable Devices and Artificial Intelligence in RWE    
            
5.    Regulatory Analysis
        5.1.     Introduction
        5.2.    North America
        5.3.    Europe
        5.4.    Asia-Pacific
        5.5.    Rest of the World
                
6.    Pricing Models
        6.1.    Introduction
        6.2.    Pay Per Patient Record (Volume-Based Pricing)
        6.3.    Pay Per Usage (Value-Based Pricing)
        6.4.    Annual Subscription
                    
7.    Global Real-World Evidence Solutions Market, by Component        
        7.1. Introduction         
        7.2. Datasets        
                   7.2.1.     Disparate Datasets    
                                 7.2.1.1. EMR/EHR/Clinical Data
                                 7.2.1.2. Claims & Billing Data
                                 7.2.1.3. Pharmacy Data
                                 7.2.1.4. Product/Disease Registries Data
                                 7.2.1.5. Others 
                   7.2.2.     Integrated Datasets    
        7.3    Services    
                    
8.    Global Real-World Evidence Solutions Market, by Application            
        8.1.     Introduction         
        8.2.    Drug Development & Approvals        
                   8.2.1    Oncology    
                   8.2.2    Cardiovascular Disease    
                   8.2.3    Neurology    
                   8.2.4    Immunology    
                   8.2.5    Others Therapeutic Areas     
        8.3.    Medical Device Development & Approvals        
        8.4.    Market Access & Reimbursement/Coverage Decisions        
        8.5.    Clinical Decision-Making        
        8.6.    Other Applications     
                    
9.    Global Real-World Evidence Solutions Market, by End User            
        9.1.     Introduction         
        9.2.     Pharmaceutical, Biotechnology & Medical Device Companies        
        9.3.     Healthcare Payers    
        9.4.     Healthcare Providers        
        9.5.     Other End Users         
            
10.    Global Real-World Evidence Solutions Market, by Geography            
          10.1.      Introduction         
          10.2.     North America         
                        10.2.1.     U.S.     
                        10.2.2.     Canada     
          10.3.     Europe         
                         10.3.1.     Germany     
                         10.3.2.     France     
                         10.3.3.      U.K.     
                         10.3.4.      Italy    
                         10.3.5.     Spain    
                         10.3.6.     Rest of Europe     
          10.4.     Asia-Pacific         
                        10.4.1.     Japan     
                        10.4.2.     China     
                        10.4.3.     Rest of Asia-Pacific    
          10.5.     Latin America         
          10.6.    Middle East & Africa     

11.     Competitive Landscape
          11.1.    Introduction
          11.2.    Key Growth Strategies
          11.3.    Competitive Benchmarking
                       11.3.1.    Competitive Benchmarking, by Methodology
          11.4.    Market Share Analysis (2019)
                
12.    Company Profiles             
          12.1.     IQVIA Holdings Inc. (U.S.)        
          12.2.      ICON plc (Ireland)        
          12.3.      Parexel International Corporation (U.S.)    
          12.4.      PPD Inc. (U.S.)    
          12.5.     International Business Machines Corporation (U.S.)        
          12.6.      UnitedHealth Group Incorporated (U.S.)        
          12.7.      Oracle Corporation (U.S.)    
          12.8.     SAS Institute Inc. (U.S.)        
          12.9.     Anthem Inc. (U.S.)        
          12.10     Clinigen Group plc (U.K.)        
          12.11     Cognizant Technology Solutions (CTS) Corporation        
          12.12.    PerkinElmer, Inc. (U.S.)    
                    
13.    Appendix             
          13.1.     Questionnaire        
          13.2.     Available Customization         

List of Tables

Table 1     Global Real-World Evidence Solutions Market Drivers: Impact Analysis (2020-2027)
Table 2     Global Real-World Evidence Solutions Market Restraints: Impact Analysis (2020-2027)
Table 3     Global Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 4     Global Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 5     Global Real-World Evidence Solutions Datasets Market Size, by Country/Region 2018-2027 (USD Million)
Table 6     Global Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 7     Global Real-World Evidence Solutions Disparate Datasets Market Size, by Country/Region, 2018-2027 (USD Million)
Table 8     Global EMR/EHR/Clinical Datasets Market Size for RWE Solutions by Country/Region, 2018-2027 (USD Million)
Table 9     Global Claims & Billing Data Market Size for RWE Solutions by Country/Region, 2018-2027 (USD Million)
Table 10     Global Pharmacy Data Market Size for RWE Solutions by Country/Region, 2018-2027 (USD Million)
Table 11     Global Product/Disease Registries Data Market Size for RWE Solutions by Country/Region, 2018-2027 (USD Million)
Table 12     Global Other Disparate Datasets Market Size for RWE Solutions by Country/Region, 2018-2027 (USD Million)
Table 13   Global Real-World Evidence Solutions Integrated Datasets Market Size, by Country/Region, 2018-2027 (USD Million)
Table 14     Global Services Market Size for RWE Solutions by Country/Region, 2018-2027 (USD Million)
Table 15     Global Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 16    Global RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2018-2027 (USD Million)
Table 17     Global RWE Solutions Market Size for Drug Development & Approvals, by Country/Region, 2018-2027 (USD Million)
Table 18     Global RWE Solutions Market Size for Oncological Drug Development & Approvals, by Country/Region, 2018-2027 (USD Million)
Table 19     Global RWE Solutions Market Size for Cardiovascular Drug Development & Approvals, by Country/Region, 2018-2027 (USD Million)
Table 20     Global RWE Solutions Market Size for Neurology Drug Development & Approvals, by Country/Region, 2018-2027 (USD Million)
Table 21     Global RWE Solutions Market Size for Immunology Drug Development & Approvals, by Country/Region, 2018-2027 (USD Million)
Table 22     Global RWE Solutions Market Size for Other Therapeutic Areas Drug Development & Approvals, by Country/Region, 2018-2027 (USD Million)
Table 23     Global RWE Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2018-2027 (USD Million)
Table 24     Global RWE Solutions Market Size for Clinical Decision Making, by Country/Region, 2018-2027 (USD Million)
Table 25     Global RWE Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2018-2027 (USD Million)
Table 26     Global RWE Solutions Market Size for Other Applications, by Country/Region, 2018-2027 (USD Million)
Table 27         Global Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 28     Global Real-World Evidence Solutions Market Size, for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2018-2027 (USD Million)
Table 29     Global Real-World Evidence Solutions Market Size, for Healthcare Payers, by Country/Region, 2018-2027 (USD Million)
Table 30     Global Real-World Evidence Solutions Market Size, for Healthcare Providers, by Country/Region, 2018-2027 (USD Million)
Table 31     Global Real-World Evidence Solutions Market Size, for Other End Users, by Country/Region, 2018-2027 (USD Million)
Table 32     Global Real-World Evidence Solutions Market Size, by Country/Region, 2018-2027 (USD Million)
Table 33     North America: Real-World Evidence Solutions Market Size, by Country, 2018-2027 (USD Million)
Table 34     North America: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 35     North America: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 36     North America: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 37     North America: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 38     North America: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 39     U.S.: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 40     U.S.: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 41     U.S.: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 42     U.S.: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 43      U.S.: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 44     Canada: Real -World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 45     Canada: Real -World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 46     Canada: Real -World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 47     Canada: Real -World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 48      Canada: Real -World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 49     European: Real-World Evidence Solutions Market Size, by Country, 2018-2027 (USD Million)
Table 50     European: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 51     European: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 52     European: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 53      European: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 54      European: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 55     Germany: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 56     Germany: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 57     Germany: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 58     Germany: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 59     Germany: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 60     U.K.: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 61     U.K.: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 62     U.K.: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 63     U.K.: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 64     U.K.: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 65     France: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 66     France: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 67     France: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 68     France: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 69     France: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 70     Italy: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 71     Italy: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 72     Italy: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 73     Italy: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 74      Italy: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 75      Spain: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 76      Spain: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 77      Spain: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 78      Spain: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 79       Spain: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 80       RoE: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 81       RoE: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 82       RoE: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 83         RoE: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 84         RoE: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 85         Asia-Pacific: Real-World Evidence Solutions Market Size, by Country, 2018-2027 (USD Million)
Table 86          Asia-Pacific: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 87         Asia-Pacific: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 88         Asia-Pacific: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 89     Asia-Pacific: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 90     Asia-Pacific: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 91     Japan: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 92     Japan: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 93     Japan: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 94      Japan: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 95      Japan: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 96     China: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 97     China: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 98     China: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 99      China: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 100     China: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 101     RoAPAC: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 102     RoAPAC: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 103     RoAPAC: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 104     RoAPAC: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 105     RoAPAC: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 106     Latin America: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 107     Latin America: Real-World Evidence Solutions Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 108     Latin America: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 109     Latin America: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 110     Latin America: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 111     Middle East & Africa: Real-World Evidence Solutions Market Size, by Component, 2018-2027 (USD Million)
Table 112     Middle East & Africa: Real-World Evidence Solutions Datasets Market Size, by Type, 2018- 2027 (USD Million)
Table 113     Middle East & Africa: Real-World Evidence Solutions Disparate Datasets Market Size, by Type, 2018-2027 (USD Million)
Table 114     Middle East & Africa: Real-World Evidence Solutions Market Size, by Application, 2018-2027 (USD Million)
Table 115     Middle East & Africa: Real-World Evidence Solutions Market Size, by End User, 2018-2027 (USD Million)
Table 116     Recent Developments, by Company, 2017-2020            

List of Figures

Figure 1         Research Process
Figure 2         Key Secondary Sources
Figure 3         Primary Research Techniques
Figure 4         Key Executives Interviewed
Figure 5         Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6         Market Size Estimation
Figure 7      Global Real-World Evidence Solutions Market Size, by Component, 2020 Vs. 2027 (USD Million)
Figure 8       Global Real-World Evidence Solutions Market Size, by Application, 2020 Vs. 2027 (USD Million)
Figure 9       Regional Snapshot: Real-World Evidence Solutions Market
Figure 10     Global Real-World Evidence Solutions Market Size, by Component, 2020-2027 (USD Million)
Figure 11     Global Real-World Evidence Solutions Market Size, by Application, 2020-2027 (USD Million)
Figure 12     Global Real-World Evidence Solutions Market Size, by End User, 2020-2027 (USD Million)
Figure 13     Global Real-World Evidence Solutions Market Size, by Country/Region, 2020-2027 (USD Million)
Figure 14     North America: Real-World Evidence Solutions Market Snapshot
Figure 15     Europe: Real-World Evidence Solutions Market Snapshot
Figure 16     Asia-Pacific: Real-World Evidence Solutions Market Snapshot
Figure 17     Key Growth Strategies Adopted by Leading Players, 2017-2020
Figure 18     Real-World Evidence Solutions Market: Competitive Benchmarking

COVID-19

This report provides pre & post COVID-19 market estimates

Download sample here

The Real-World Evidence (RWE) Solutions market is projected to reach USD 3.13 billion by 2027 from USD 1.08 billion in 2020, at a CAGR of 16.5% during the forecast period. The growing geriatric population and burden of chronic diseases, shift towards value-based care, rising focus on the use of personalized healthcare, retardation in drug development process thereby leading to increase in developmental costs, and expedite the use of RWE for regulatory decision making are expected to propel the real-world evidence solutions market. In addition, emerging markets, rising focus on end-to-end RWE services, and evolving roles of wearable devices, social media, and AI in RWE represent high-growth opportunities for players operating in the real-world evidence solutions market.

Impact of COVID-19 on Real-World Evidence (RWE) Solutions Market

As the COVID-19 outbreak continues to take its toll on global markets, real-world evidence solutions will be affected in the upcoming years. The COVID-19 pandemic has put a tremendous burden on the healthcare sector all over the world. With the unavailability of treatment, rise in cases, limited resources, and vulnerability of the medical staff, the healthcare sector is struggling to deal with the pandemic situation. Real-world evidence solutions can provide valuable insights to better understand, monitor, and prepare for the challenges caused by the pandemic.

Understanding where and how quickly the outbreak is likely to spread, the same tracking models could be adapted to fight any upcoming COVID-19 outbreaks. Amidst the pandemic, a systematic approach for generating information to support clinical and public health decision making is needed. Real-world data (RWD), captured directly from patients or through medical claims or electronic medical records (EMRs), has the potential to inform COVID-19 research in ways randomized clinical trials (RCT) will not.

The FDA is leveraging real-world data to understand COVID-19 risk factors better, tailor public health interventions to specific communities, and mitigate the spread of the virus. The organization is participating in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder collaborative project that advances the development of diagnostics. The effort is coordinated by the Reagan-Udall Foundation for the FDA in collaboration with Friends of Cancer Research. The Diagnostics Evidence Accelerator will evaluate the real-world performance of COVID-19 diagnostic tests and antibody tests and how they are best used to tailor testing strategies to specific populations. Thus, the pandemic will lead to increased adoption of RWE solutions in the upcoming years.

Delays in Drug Development and the Subsequent Increase in Development Costs is Expected to Propel the Market Growth

With the inclination towards personalized healthcare and hike in the emergence of rare diseases, the healthcare and research organizations are facing challenges posed by high costs and lengthy timelines of delivering medicines to patients as the development of new pharmaceutical entity is time-consuming, extremely costly, and of high risk with little chance of successful outcome.

In addition, pharmaceutical companies conduct clinical trials to gain approval from regulatory bodies, which is considered an essential part of the drug development process. However, the increasing cost and time-consuming clinical trials discourage pharmaceutical companies from conducting drug development, limiting patients’ access to novel treatments. Due to the high cost of drug development and clinical trials, many companies are looking for possible ways to cut down the cost of clinical trials and avoid drug development barriers to accelerate the drug development process. The adoption of real-world evidence helps simplify access and address some of the burdens while also providing a better understanding of medicines use in the real world.

Key Findings of the Real-world evidence solutions market Study:

In 2020, the datasets segment to dominate the real-world evidence solutions market

Factors such as the rising attention for additional insights on epidemiology; compliance, adherence, and costs in a realistic environment; growth in the volume of medical data generated in hospitals and healthcare facilities; dependence of outcome-based studies on real-world data; and growth in the demand for information by payers, regulatory bodies, and providers with regards to drug safety are driving the growth of the datasets segment. The real-world datasets market is further segmented into disparate and integrated datasets.

The market access & reimbursement/coverage decisions segment is expected to grow at the highest CAGR during the forecast period

Based on application, the market access & reimbursement/coverage decisions segment is expected to grow at the highest CAGR due to increasing therapy costs and increasing focus towards clinical value evidence for making decisions to provide coverage.

In 2020, pharmaceutical, biotech & medical device companies to account for the largest share of this market

Factors such as the increasing need to prevent costly drug recalls, growing importance of RWE studies in drug development and approvals, and inclination towards assessing drug performance in real-world settings support the growth of this end-user segment.

North America: Fastest Growing Market

At the regional level, North America is estimated to account for the largest share of the RWE solutions market in 2020 and is also expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of the North American market can be attributed to the availability of real-world datasets, growing focus on value-based care, rising R&D expenditure by the biopharma companies, emphasis on early drug/device development & approvals, and presence of major RWE players in the region.

Key Players

The report includes a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the past five years (2017-2020). The key players profiled in the real-world evidence solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA (U.S.), Optum (a subsidiary of United Health Group, Inc.) (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD Inc., (U.S.), SAS Institute Inc. (U.S.), and Syneos Health, Inc. (U.S.), among others.

Scope of the Report:

Real-world Evidence Solutions Market, by Component

  • Datasets
    • Disparate Datasets
  • EMR/EHR/Clinical data
  • Claims & billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Other Disparate Datasets
    • Integrated Datasets
  • Services
    (Other disparate datasets comprise data gathered from other sources that can inform health statuses, such as mobile devices, wearable devices, and social media.)

Real-world Evidence Solutions Market, by Application

  • Drug Development & Approvals
    • Oncology
    • Cardiovascular Disease
    • Neurology
    • Immunology
    • Others Therapeutic Areas
      (Other therapeutic areas comprise infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases.)
  • Medical Device Development & Approvals
  • Market Access & Reimbursement/Coverage Decisions
  • Clinical Decision-making
  • Other Applications
    (Other applications comprise regulatory decision-making, post-approval monitoring, and post-market device surveillance. )

Real-world Evidence Solutions Market, by End User

  • Pharmaceutical, Biotechnology & Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users
    (Other end-users comprise academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies.)

Real-world Evidence Solutions Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key questions answered in the report:

The real-world evidence solutions (RWE) market covers the data sets' market size & forecasts like the disparate and integrated data sets and consulting services. The RWE market studied in this report involves the value analysis of various segments and sub-segments of real-world evidence solutions (RWE) at regional and country levels.
The real-world evidence solutions (RWE) market projected to reach USD 5,573.9 million by 2027, at a CAGR of 19.1% during the forecast period.
Based on component, the data sets segment is estimated to account for the largest share of the overall RWE solutions market in 2020. Moreover, this segment is further expected to grow with the fastest CAGR during the forecast period.
Based on application, the drug development and approvals application segment is projected to create more traction with the fastest CAGR during the forecast period owing to the increase in the demand of RWD and RWE to accelerate drug discovery and development, increasing investment by biopharmaceutical companies in R&D, and growing inclination of regulatory bodies towards RWE.
Overall growth in the geriatric population globally and rising prevalence of chronic diseases, focus towards value-based care, attention on personalized healthcare, delays in drug development and the subsequent increase in development costs, and expanding use of RWE for regulatory decision making are the factors driving the market growth. In addition, growth prospects from the emerging markets, rising need for end-to-end RWE services, emerging roles of wearable devices, social media, and AI in RWE represent high-growth opportunities for players operating in the real-world evidence solutions market.
The key players operating in the real-world evidence solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA (U.S.), Optum (A Subsidiary of United Health Group, Inc.) (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD Inc., (U.S.), SAS Institute Inc. (U.S.), and Syneos Health, Inc. (U.S.) among others.
The emerging countries from Asia-Pacific are projected to offer significant growth opportunities for the vendors in this market owing to the “Rational Medicine” initiative in an attempt to make the Japanese health care system more patient-centric and evidence-based while some countries like China and others are fast adopters in terms of RWE collection and use.
This website is secure and we do not share your personal information with any third party. Privacy Policy
Tags: Healthcare IT Connected Health / Digital Health Healthcare Medical Technologies Neurology Immunology Oncology Cardiovascular Disease
Download Free Sample